Roche signs onto Alnylam’s mid-stage hypertension med for $310 million upfront
Phase 1Phase 2Clinical ResultPhase 3
Preview
Source: FierceBiotech
Alnylam planned to release interim data on hypertension med zilebesiran in the middle of the year.
Roche is hitching its wagon to Alnylam’s mid-stage hypertension med, zilebesiran, and coughing up $310 million in upfront cash for the journey.
The new partnership gives the Swiss pharma full ex-U.S. rights to the drug and co-U.S. rights alongside Alnylam, in exchange for the $310 million plus up to $2.8 billion in potential milestone payments. The two companies will co-commercialize and split profits of the drug in the U.S., according to Monday's announcement.
Alnylam will lead the joint development of the asset through its first indication, currently listed as hypertension, with both companies splitting costs. Roche will have the opportunity to spearhead the development for any future indications.
Alnylam CEO Yvonne Greenstreet said that the partnership allows Alnylam to “develop zilebesiran in a more robust way,” specifically by having cardiovascular outcomes data available at the time of a potential launch.
The treatment is currently in two phase 2 trials, including a placebo-controlled study testing zilebesiran in patients with mild to moderate hypertension. Recruitment for that trial—which was aiming to enroll almost 400 participants—wrapped up in February. Patients will receive either zilebesiran or placebo for the first six months of the trial before placebo patients are randomized to one of four potential treatment doses. Alnylam planned to report interim data from the trial midway through the year but has yet to do so.
Another larger phase 2 study is testing zilebesiran as an add-on therapy to Pfizer’s Norvasc, Daiichi Sankyo’s Benicar and indapamide. Recruitment is still ongoing in that trial with more than 600 patients expected to be enrolled.
Zilebesiran offered a glimmer of promise in its phase 1 results, showing a dose-dependent reduction in a particular gene associated with hypertension and blood pressure control that persisted for up to six months at dose levels of at least 200 mg. The primary endpoint of the monotherapy phase 2 trial is the change from baseline in 24-hour blood pressure at the three-month mark following treatment.
The deal serves as a significant entry for Roche in the metabolic space, where it has few contenders. The company’s current pipeline lists RG6359, a treatment for Pompe disease, as the only clinical-stage metabolic asset.
Editor's note: This story was updated to include the amount of potential milestone payments.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.